Consistent with the dominant role of CD4+ Th2 cells in mediating TSLP’s antitumor effects during early carcinogenesis (11, 13), topical TSLP induction by calcipotriol treatment results in the induction of CD4+ Th2 cell immunity against late-stage breast cancer progression. The gene discussed is CD4; the disease is breast carcinoma.